tiprankstipranks
Humana Inc (CH:HUM)
:HUM

Humana (HUM) Price & Analysis

3 Followers

HUM Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Durable Revenue Growth & MA ScaleConsistent mid-single-digit TTM revenue growth driven by Medicare Advantage and government products underpins scale and predictable capitated cash flows. That steadiness supports underwriting discipline, provider contracting leverage, and multi-quarter investment in CenterWell and care programs that improve long-term cost control.
Operational Cost Reductions And Margin RoadmapManagement’s execution on centralization, outsourcing, and vendor transformation has already produced meaningful G&A savings and hundreds of millions of dollars of value. Those structural cost moves should sustainably improve operating leverage and materially contribute to the multi-year path toward a targeted sustainable pretax MA margin.
Enhanced Liquidity & Capital FlexibilityPre-capitalized contingent facilities plus monetization of a non-core stake increase committed liquidity and optionality. This durable improvement in capital flexibility helps fund reserves, margin initiatives, and strategic expansion (e.g., Medicaid wins, CenterWell growth) while limiting forced balance-sheet moves under stress.
Bears Say
Compressed Profitability And Weak ROEMargins and returns have materially declined versus prior years, leaving a thin earnings cushion against medical cost shocks. Low profitability constrains internal reinvestment and shareholder returns, and increases sensitivity to reserve volatility and trend, making near-term margin recovery dependent on sustained operational wins.
Elevated Drug-Cost TrendPersistently high drug trend is a structural headwind for Part D and MA underwriting margins because drug inflation directly widens medical spend. With new drugs entering the market and limited short-term offsets, sustained elevated pharmacy trend will pressure margins and require either higher premiums, stronger rebates, or deeper medical offset.
Membership Disruption & Mix RiskLarge planned plan exits materially alter member composition and revenue base; recapture is uncertain and historically partial. Because MA profitability depends on risk-adjusted membership mix, this structural churn reduces visibility into near-term margins and could blunt the impact of cost initiatives if higher-cost cohorts dominate renewals.

Humana News

HUM FAQ

What was Humana Inc’s price range in the past 12 months?
Currently, no data Available
What is Humana Inc’s market cap?
Humana Inc’s market cap is CHF36.42B.
    When is Humana Inc’s upcoming earnings report date?
    Humana Inc’s upcoming earnings report date is Nov 06, 2026 which is in 85 days.
      How were Humana Inc’s earnings last quarter?
      Humana Inc released its earnings results on Jul 29, 2026. The company reported CHF6.183 earnings per share for the quarter, beating the consensus estimate of CHF5.906 by CHF0.278.
        Is Humana Inc overvalued?
        According to Wall Street analysts Humana Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Humana Inc pay dividends?
          Humana Inc does not currently pay dividends.
          What is Humana Inc’s EPS estimate?
          Humana Inc’s EPS estimate is -0.77.
            How many shares outstanding does Humana Inc have?
            Humana Inc has 120,080,310 shares outstanding.
              What happened to Humana Inc’s price movement after its last earnings report?
              Humana Inc reported an EPS of CHF6.183 in its last earnings report, beating expectations of CHF5.906. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Humana Inc?
                Currently, no hedge funds are holding shares in CH:HUM
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Humana Inc

                  Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.

                  Humana (HUM) Earnings & Revenues

                  HUM Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call conveyed a generally constructive operational and strategic progress narrative: clear cost-reduction execution (120 bps Y/Y improvement in Q2 operating cost ratio and expected ~150 bps full-year), tangible improvement in key Stars-related measures (outperforming historical CAGR on most selected metrics and ~5% better quality improvement rate for BY '29 measures), balance-sheet moves (Gentiva divestiture ~ $900M and $1.5B P-Cap facilities) and a new statewide Medicaid win. However, material risks remain — notably elevated and rising drug trend, dependence on membership mix for margin realization, plan-exit disruption (~600k members), elevated reserves/IBNR, and Stars/ policy uncertainty — which temper the outlook. On balance, the highlights (execution, cost savings, Stars operational progress, capital actions) outweigh the lowlights (policy uncertainty, drug trend, membership disruption), producing a cautiously positive sentiment.View all CH:HUM earnings summaries

                  HUM Revenue Breakdown

                  94.73%94.73%4.50%0.78%
                  94.73% Premiums
                  4.50% Services
                  0.78% Investment income
                  tipranks

                  HUM Stock 12 Month Forecast

                  Average Price Target

                  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
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Centene
                  Cigna
                  CVS Health
                  UnitedHealth
                  Elevance Health
                  Popular Stocks